[go: up one dir, main page]

JOP20220184A1 - علاج مصابي السرطان ممن لديهم طفرات تخطي c-Met إكسون14 - Google Patents

علاج مصابي السرطان ممن لديهم طفرات تخطي c-Met إكسون14

Info

Publication number
JOP20220184A1
JOP20220184A1 JOP/2022/0184A JOP20220184A JOP20220184A1 JO P20220184 A1 JOP20220184 A1 JO P20220184A1 JO P20220184 A JOP20220184 A JO P20220184A JO P20220184 A1 JOP20220184 A1 JO P20220184A1
Authority
JO
Jordan
Prior art keywords
treatment
patients
met exon
skipping
mutations
Prior art date
Application number
JOP/2022/0184A
Other languages
English (en)
Inventor
Sheri Moores
Sylvie Laquerre
Roland Knoblauch
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of JOP20220184A1 publication Critical patent/JOP20220184A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G01N33/5752—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

يتعلق الاختراع الحالي بمعالجة مشاركين في الدراسة مصابين بسرطان لديهم طفرات تخطي c-Met إكسون 14.
JOP/2022/0184A 2020-02-12 2021-02-10 علاج مصابي السرطان ممن لديهم طفرات تخطي c-Met إكسون14 JOP20220184A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062975406P 2020-02-12 2020-02-12
PCT/IB2021/051203 WO2021161262A1 (en) 2020-02-12 2021-02-12 TREATMENT OF PATIENTS HAVING c-MET EXON 14 SKIPPING MUTATIONS

Publications (1)

Publication Number Publication Date
JOP20220184A1 true JOP20220184A1 (ar) 2023-01-30

Family

ID=77272416

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2022/0184A JOP20220184A1 (ar) 2020-02-12 2021-02-10 علاج مصابي السرطان ممن لديهم طفرات تخطي c-Met إكسون14

Country Status (13)

Country Link
US (1) US12215160B2 (ar)
EP (1) EP4103190A4 (ar)
JP (1) JP7783182B2 (ar)
KR (1) KR20220140794A (ar)
CN (1) CN115087449A (ar)
AU (1) AU2021220009A1 (ar)
BR (1) BR112022015140A2 (ar)
CA (1) CA3170675A1 (ar)
IL (1) IL295516A (ar)
JO (1) JOP20220184A1 (ar)
MX (1) MX2022009906A (ar)
PH (1) PH12022552076A1 (ar)
WO (1) WO2021161262A1 (ar)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY208668A (en) 2019-05-14 2025-05-23 Janssen Biotech Inc Combination therapies with bispecific anti-egfr/c-met antibodies and 3rd generation egfr tyrosine kinase inhibitors
JOP20220184A1 (ar) 2020-02-12 2023-01-30 Janssen Biotech Inc علاج مصابي السرطان ممن لديهم طفرات تخطي c-Met إكسون14
US20230183360A1 (en) * 2021-12-09 2023-06-15 Janssen Biotech, Inc. Use of Amivantamab to Treat Colorectal Cancer
KR20240151848A (ko) * 2022-03-07 2024-10-18 메뤼스 엔.페. Egfr 및 cmet에 결합하는 항체를 사용한 치료
CN115354079A (zh) * 2022-09-05 2022-11-18 复旦大学附属中山医院 一种用于检测egfr靶向药物治疗适用性的试剂盒

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE87659T1 (de) 1986-09-02 1993-04-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5837242A (en) 1992-12-04 1998-11-17 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
DE60143544D1 (de) 2000-12-12 2011-01-05 Medimmune Llc Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
FR2858235B1 (fr) 2003-07-31 2006-02-17 Lab Francais Du Fractionnement Utilisation d'anticorps optimises en adcc pour traiter les patients faibles repondeurs
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
US7767792B2 (en) 2004-02-20 2010-08-03 Ludwig Institute For Cancer Research Ltd. Antibodies to EGF receptor epitope peptides
EP2439284B1 (en) 2004-03-31 2019-05-08 The General Hospital Corporation Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
WO2005118876A2 (en) 2004-06-04 2005-12-15 Genentech, Inc. Egfr mutations
US20060204493A1 (en) 2004-09-02 2006-09-14 Genentech, Inc. Heteromultimeric molecules
PL1846030T3 (pl) 2005-01-21 2019-05-31 Genentech Inc Ustalone dawkowanie przeciwciał her
JP4898710B2 (ja) 2005-02-11 2012-03-21 メモリアル スローン−ケタリング キャンサー センター 薬剤耐性ｅｇｆｒ突然変異体を検出するための方法および組成物
EA013617B1 (ru) 2005-02-24 2010-06-30 Амген Инк. Мутации рецептора эпидермального фактора роста
US7615529B2 (en) 2005-03-25 2009-11-10 Genentech, Inc. Methods and compositions for modulating hyperstabilized c-met
TWI671403B (zh) 2005-03-31 2019-09-11 中外製藥股份有限公司 控制組裝之多肽的製造方法
PT1999154E (pt) 2006-03-24 2013-01-24 Merck Patent Gmbh Domínios proteicos heterodiméricos modificados
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
DK2076289T3 (da) 2007-04-13 2015-02-09 Dana Farber Cancer Inst Inc Fremgangsmåder til behandling af cancerresistens over for ErbB-lægemider
WO2009018386A1 (en) 2007-07-31 2009-02-05 Medimmune, Llc Multispecific epitope binding proteins and uses thereof
US7892770B2 (en) 2007-08-24 2011-02-22 Van Andel Research Institute Monoclonal antibody which binds cMet (HGFR) in formalin-fixed and paraffin-embedded tissues and related methods
AU2008343589A1 (en) 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
AU2010245011B2 (en) 2009-04-27 2015-09-03 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
LT2560993T (lt) 2010-04-20 2024-10-10 Genmab A/S Baltymai, kurių sudėtyje yra heterodimerinio antikūno fc, ir jų gamybos būdai
WO2011140391A2 (en) 2010-05-05 2011-11-10 The Research Foundation Of State University Of New York Egfr-related polypeptides and methods of use
MX352929B (es) 2010-11-05 2017-12-13 Zymeworks Inc DISEÑO DE ANTICUERPOS HETERODIMÉRICOS ESTABLES CON MUTACIONES EN EL DOMINIO Fc.
ES2860748T3 (es) 2011-01-24 2021-10-05 Gilead Sciences Inc Anticuerpos selectivos para células que presentan EGFR con alta densidad
MX358752B (es) 2011-03-25 2018-08-31 Glenmark Pharmaceuticals Sa Inmunoglobulinas heterodiméricas.
KR20130036993A (ko) 2011-10-05 2013-04-15 삼성전자주식회사 ｃ-Ｍｅｔ의 ＳＥＭＡ 도메인 내의 에피토프에 특이적으로 결합하는 항체
HUE065876T2 (hu) 2011-10-11 2024-06-28 Hoffmann La Roche Bispecifikus antitestek javított összeállítása
HUE056462T2 (hu) 2011-11-04 2022-02-28 Zymeworks Inc Stabil heterodimer antestest tervezés mutációkkal az FC domainben
SMT201800624T1 (it) 2012-11-21 2019-01-11 Janssen Biotech Inc Anticorpi egfr/c-met bispecifici
US20170275367A1 (en) 2012-11-21 2017-09-28 Janssen Biotech, Inc. Bispecific EGFR/C-Met Antibodies
WO2015043614A1 (en) 2013-09-26 2015-04-02 Biontech Ag Methods and compositions for prediction of therapeutic efficacy of cancer treatments and cancer prognosis
SG11201607143UA (en) 2014-03-11 2016-09-29 Univ Leland Stanford Junior Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies
CN111875585B (zh) 2014-06-12 2023-06-23 上海艾力斯医药科技股份有限公司 一类激酶抑制剂
PT3929190T (pt) 2014-10-13 2025-02-19 Yuhan Corp Compostos e composições para modular atividades da cinase do mutante de egfr
EP3221358B1 (en) 2014-11-18 2021-07-21 Janssen Pharmaceutica, N.V. Cd47 antibodies, methods, and uses
WO2016149265A1 (en) * 2015-03-16 2016-09-22 Kolltan Pharmaceuticals, Inc. Anti-met antibodies and methods of use thereof
MA45517B1 (fr) 2015-10-23 2021-04-30 Merus Nv Molécules de liaison inhibant la croissance de cancer
EP4606820A3 (en) 2015-11-30 2025-10-29 Medimmune, LLC Optimized ratios of amino acids and sugars as amorphous stabilizing compounds in pharmaceutical compositions containing high concentrations of protein-based therapeutic agents
JP6911019B2 (ja) 2016-05-17 2021-07-28 公益財団法人がん研究会 Ｅｇｆｒ−ｔｋｉ耐性を獲得した肺癌の治療薬
WO2017205465A2 (en) 2016-05-24 2017-11-30 Griswold Karl Edwin Antibodies and methods of making same
GB201611123D0 (en) 2016-06-27 2016-08-10 Euremab Srl Anti met antibodiesand uses thereof
EP3512882B1 (en) 2016-09-14 2021-03-10 Merck Patent GmbH Anti-c-met antibodies and antibody drug conjugates thereof for efficient tumor inhibition
JP7265985B2 (ja) 2016-11-17 2023-04-27 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Ｅｇｆｒまたはｈｅｒ２のエクソン２０変異を有するがん細胞に対する抗腫瘍活性を有する化合物
CA3054381A1 (en) 2017-02-22 2018-08-30 University Of Saskatchewan Egfr-binding agents and uses thereof
AR111469A1 (es) 2017-04-21 2019-07-17 Yuhan Corp Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma
JP2020521216A (ja) 2017-05-19 2020-07-16 ガーダント ヘルス， インコーポレイテッド 挿入および欠失を検出するための方法およびシステム
MA49703A (fr) 2017-07-28 2021-04-21 Yuhan Corp Nouveaux intermédiaires utiles pour la synthèse de dérivés d'aminopyrimidine, leur procédé de préparation et procédé de préparation de dérivés d'aminopyrimidine à l'aide de ceux-ci
DK3658547T3 (da) 2017-07-28 2023-10-16 Yuhan Corp Fremgangsmåde til fremstilling af n-(5-(4-(4-formyl-3-phenyl-1h-pyrazol-1-yl)pyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamid
MX2022008743A (es) 2017-07-28 2023-02-02 Yuhan Corp Proceso mejorado para preparar derivados de aminopirimidina.
EP3847283A4 (en) 2018-09-04 2022-11-16 Rain Therapeutics Inc. COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATMENT OR PREVENTION OF MANAGED CANCER
KR20200043618A (ko) 2018-10-18 2020-04-28 주식회사유한양행 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물
CA3131654A1 (en) 2019-02-26 2020-09-03 Janssen Biotech, Inc. Combination therapies and patient stratification with bispecific anti-egfr/c-met antibodies
MX2021011948A (es) 2019-03-29 2022-01-04 Univ Texas Compuestos con actividad antitumoral contra células cancerígenas que llevan inserciones de exon 20 effr o her2.
EP3956035A4 (en) 2019-04-17 2023-01-25 Board of Regents, The University of Texas System ANTI-CANCER LINKS WITH TYROSINE KINASE RESISTANT EGFR MUTATIONS
WO2020214831A1 (en) 2019-04-17 2020-10-22 Board Of Regents, The University Of Texas System Compounds with anti-tumor activity against cancer cells bearing tyrosine kinase inhibitor resistant egfr mutations
US11850248B2 (en) 2019-05-14 2023-12-26 Yuhan Corporation Therapies with 3rd generation EGFR tyrosine kinase inhibitors
MY208668A (en) 2019-05-14 2025-05-23 Janssen Biotech Inc Combination therapies with bispecific anti-egfr/c-met antibodies and 3rd generation egfr tyrosine kinase inhibitors
JOP20220184A1 (ar) 2020-02-12 2023-01-30 Janssen Biotech Inc علاج مصابي السرطان ممن لديهم طفرات تخطي c-Met إكسون14

Also Published As

Publication number Publication date
US20210253717A1 (en) 2021-08-19
JP2023513297A (ja) 2023-03-30
US12215160B2 (en) 2025-02-04
CA3170675A1 (en) 2021-08-19
PH12022552076A1 (en) 2023-11-29
BR112022015140A2 (pt) 2022-10-11
WO2021161262A1 (en) 2021-08-19
CN115087449A (zh) 2022-09-20
IL295516A (en) 2022-10-01
JP7783182B2 (ja) 2025-12-09
KR20220140794A (ko) 2022-10-18
AU2021220009A1 (en) 2022-10-06
EP4103190A4 (en) 2024-07-03
EP4103190A1 (en) 2022-12-21
MX2022009906A (es) 2022-11-14

Similar Documents

Publication Publication Date Title
JOP20220184A1 (ar) علاج مصابي السرطان ممن لديهم طفرات تخطي c-Met إكسون14
MA52486B1 (fr) Pyridazinones utilisés en tant qu'inhibiteurs de parp7
BR112019010020A2 (pt) compostos com atividade anti-tumoral contra células cancerosas contendo mutações de egfr ou her2 exon 20
ECSP21093541A (es) Compuestos para el tratamiento de enfermedades y trastornos asociados con braf
PH12021551455A1 (en) Jak1 pathway inhibitors for the treatment of gastrointestinal disease
EA201690265A2 (ru) Фармацевтические композиции, содержащие замещенные ациланилиды
MX2023002362A (es) Tratamiento de cáncer de pulmón de células no pequeñas con mutaciones en el receptor del factor de crecimiento epidérmico (egfr).
EA201890767A1 (ru) C4-модифицированные производные олеаноловой кислоты для ингибирования il-17 и других применений
DE602005015687D1 (de) Phospholipid-analoga für die behandlung von krebs
GEP20257840B (en) Tyk2 pseudokinase ligands
EA202192905A1 (ru) Соединения, содержащие n-метил-2-пиридон, и фармацевтически приемлемые соли
MX2017016134A (es) Aril dihidro-2h-benzo[b][1,4]oxazina sulfonamida y compuestos relacionados para uso como agonistas de rory y el tratamiento de enfermedad.
EA202192625A1 (ru) Лиганды псевдокиназы tyk2
MX2023007998A (es) Regimenes de tratamiento con dexmedetomidina.
MX2022006407A (es) Composiciones bacterianas diseñadas y usos de estas.
EP3831412A4 (en) TREATMENT OF METASTATIC BRAIN TUMOR BY ADMINISTRATION OF AN ANTIBODY-DRUG CONJUGATE
EA202192288A1 (ru) Соединения на основе нейрегулина-4 и способы их применения
MX2024006769A (es) Compuestos y usos de los mismos.
JOP20200304A1 (ar) مركبات بنزينسلفوناميد واستخدامها كعوامل علاجية
MX2021000011A (es) Derivados fosfonato y fosfato de 7-amino-5-tio-tiazol[4,5-d]pirimi dinas y su uso en el tratamiento de afecciones asociadas con niveles elevados de cx3cr1 y/o cx3cl1.
EP4069700A4 (en) MACROCYCLES FOR USE IN TREATMENT OF DISEASES
EA202190755A1 (ru) Агенты для терапии и диагностики рака
MX2022011844A (es) Terapia combinada con un inhibidor de idh mutante.
PH12020551495A1 (en) Compounds with anti-tumor activity against cancer cells bearing her2 exon 19 mutations
EA201500579A1 (ru) Комбинированная терапия с использованием воласертиба